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Background: Transient episodes of ischemia in a remote organ (remote ischemic preconditioning, RIPC) can
attenuate myocardial ischemia/reperfusion injury but the underlying mechanisms of RIPC in the target organ are
still poorly understood. Recent animal studies suggested that the small redox protein thioredoxin may be a
potential candidate for preconditioning-induced organprotection. Here we employed a human proteome profiler
array to investigate the RIPC regulated expression of cell stress proteins and particularly of thioredoxin in heart
tissue of cardiosurgical patients with cardiopulmonary bypass (CPB).
Methods: RIPC was induced by four 5 minute cycles of transient upper limb ischemia/reperfusion using a blood
pressure cuff. Right atrial tissue was obtained from patients receiving RIPC (N = 19) and control patients (N = 19)
before and after CPB. Cell stress proteome profiler arrays as well as Westernblotting and ELISA experiments for
thioredoxin (Thio-1) were performed employing the respective tissue samples.
Results: Protein arrays revealed an up-regulation of 26.9% (7/26; CA IX, Cyt C, HSP-60, HSP-70, pJNK, SOD2, Thio-1)
of cell stress associated proteins in RIPC tissue obtained before CPB, while 3.8% (1/26; SIRT2) of the proteins were
down-regulated. Array results for thioredoxin were verified by semi-quantitative Westernblotting studies which
showed a significant up-regulation of thioredoxin protein levels in cardiac tissue samples of RIPC patients taken
before CPB (RIPC: 5.36 ± 0.85 a.u.; control: 3.23 ± 0.39 a.u.; P < 0.05). Quantification of thioredoxin levels in tissue of
RIPC and control patients by ELISA experiments further confirmed the Westernblotting results (RIPC: 0.30 ± 0.02 ng/mg
protein; control: 0.24 ± 0.02 ng/mg protein; P < 0.05).
Conclusion: We provide evidence for thioredoxin as a RIPC-induced factor in heart tissue of cardiosurgical patients
and identified several cell stress associated proteins that are regulated by RIPC and may play a role in RIPC-mediated
cardioprotection.
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Ischemia/reperfusion injury is commonly found during
cardiac surgery and can lead to myocardial and neuro-
logical dysfunction as well as increased mortality [1-3].
In the last decades it has been shown that transient epi-
sodes of ischemia (ischemic preconditioning) if applied be-
fore prolonged ischemia/reperfusion injury have the
potential to reduce myocardial infarction [4-9]. Subsequent
trials revealed that ischemic preconditioning does not only
act locally, but is also able to protect remote tissues from
ischemia/reperfusion injury, a phenomenon described as
remote ischemic preconditioning (RIPC). RIPC can be in-
duced by inflation and deflation of a blood pressure cuff lo-
cated at the upper or lower limb. This procedure has been
shown to attenuate myocardial injury in a number of clin-
ical situations, especially during cardiac surgery [6,10-16].
RIPC-mediated signalling events within the myocardial
tissue possibly involve protein kinase C activation, phos-
phorylation of pro-survival kinases akt and erk1/2 [17-22]
and phosphorylation of STAT5 [23]. Despite the advances
in the clinical application of RIPC and increasing know-
ledge concerning the RIPC-released humoral factors and
induced signalling events, there is still an apparent lack of
information regarding the proteins that are regulated by
RIPC within the myocardial tissue [24,25]. We have re-
cently shown that the activities of matrix metallopro-
teinases 2 and 9 (MMP-2/9) as well as the expression
levels of procaspase-3 and enzymatic activities of mye-
loperoxidase are increased in heart tissue of cardio-
surgical patients receiving RIPC [26,27]. However, the
precise cellular mechanisms that are responsible for the
RIPC-mediated cardioprotection are still unclear and dis-
cussed controversially.
The thioredoxin system is one of the central antioxidant
systems in mammalian cells, maintaining a reducing en-
vironment by catalyzing electron flux from nicotinamide
adenine dinucleotide phosphate through thioredoxin re-
ductase to thioredoxin, which reduces its target proteins
using highly conserved thiol groups [28-31]. Interestingly,
several authors have suggested that thioredoxin could also
be involved in preconditioning induced cardioprotection
[32-34].
Here we performed proteomic profiling with cardiac
tissue obtained from cardiosurgical patients subjected
to RIPC or sham intervention and investigated the ex-
pression levels of 26 cell stress associated proteins. We
moreover focused on the potential role of thioredoxin
by verifying the results of the proteome profiling ap-
proach using Westernblotting and ELISA experiments.
Methods
Experimental protocol
The study protocol, patient information, and informed
consent were approved by the Ethics Committee of theUniversity Hospital Schleswig-Holstein, Campus Kiel,
Germany (Reference number: A165/08). The study was
performed in accordance with the fourth revision of the
Declaration of Helsinki (1996) and is registered at Clinical
Trials.gov (NCT00877305). Employing patient sera and
biopsy material, two experimental sub-studies have been
published recently ([26,27]; Additional file 1: Table S1).
Aim of the study was to identify cell stress associated
proteins in cardiac tissue samples of cardiosurgical pa-
tients with and without RIPC and patients included into
the study were selected based on the criteria described
earlier [26]. Each patient (age ≥ 18 years) gave written in-
formed consent to participate in the study. All types of car-
diac surgery in which cardiopulmonary bypass (CPB) was
used were included. Patients were randomized to group
RIPC or control in a double-blinded fashion. RIPC was in-
duced by four cycles of upper limb ischemia (5-minutes
blood-pressure cuff inflation to 200 mmHg and 5-minutes
cuff deflation) after induction of total intravenous anaes-
thesia (propofol and sufentanil). In patients assigned to the
control group we used four cycles of 5-minutes blood-
pressure cuff inflation to 20 mmHg and 5-minutes cuff de-
flation without any limb ischemia (Figure 1).
Demographic data, information regarding the comor-
bidities, medications and ICU (intensive care unit) data of
the patients employed in the clinical trial and experi-
mental sub-studies (NCT00877305) have been presented
recently [26,27]. Cardiac tissue of the right atrium was col-
lected from RIPC and control patients before as well as
after CPB. Serum concentrations of cardiac troponin T
(cTnT) were employed as a marker for myocardial damage
[35,36] and in all experiments patients in the RIPC group
displayed significantly lower (P < 0.001) levels of cTnT
compared to control patients (data not shown).
Cell stress proteome profiler arrays
Proteome profiling was performed using commercially
available cell stress proteome profiler arrays (R&D Systems,
Minneapolis, USA; #ARY018) and the manufacturer’s pro-
tocol provided with the assay kit. Expression levels of 26
cell stress associated proteins were evaluated in cardiac tis-
sue that was derived from cardiosurgical patients (control
and RIPC) before as well as after CPB. Equal amounts of
protein (15 μg) of each biopsy sample were pooled and ap-
plied to the respective array membrane. Densitometric
analyses of the arrays were performed using the ImageJ
1.41o software (ImageJ, NIH, USA). Only proteins with sig-
nal intensities ≥10% of the internal reference control pro-
tein spot were further analysed.
Westernblotting
Based on the results of the cell stress proteome profiler
arrays, thioredoxin was chosen as a promising candi-
date for RIPC-mediated cardioprotection [32-34] and
Figure 1 Experimental setting. RIPC was performed by 4 cycles of 5 minutes of upper arm ischemia induced with a blood pressure cuff
which was inflated to 200 mmHg. Each cycle of ischemia was followed by 5 minutes of reperfusion. In the control group 4 cycles of 5-minutes
blood-pressure cuff inflation to 20 mmHg and 5-minutes cuff deflation were applied. Cardiac biopsies were obtained before and after CPB.
CPB, cardiopulmonary bypass; RIPC, remote ischemic preconditioning.
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patient separately. Protein extraction from cardiac tis-
sue biopsies was performed with RIPA buffer containing
150 mM sodium chloride, 1.0% NP-40, 0.1% sodium
dodecyl sulfate (SDS), 1% sodium deoxycholate, 50 mM
Tris-HCl (pH 7.6; all from Sigma-Aldrich, Hamburg,
Germany). Protein concentrations were determined with a
BCA Protein Assay Kit (Pierce Biotechnology, Rockford,
USA). Samples were boiled for 5 minutes after addition
of SDS polyacrylamide gel electrophoresis (PAGE) sam-
ple buffer (62.5 mM Tris-HCl, 2% SDS, 10% glycerol,
5% β-mercaptoethanol, all from Sigma-Aldrich). An equal
amount of protein (50 μg) of each sample was separated
by 10% SDS-PAGE and transferred onto a PVDF mem-
brane (Amersham Pharmacia Biotech, Piscataway, USA).
Membranes were then incubated in blocking solution
(Starting Block T20; Fisher Scientific, Schwerte, Germany)
for 1 hour at room temperature, followed by an overnight
incubation with specific antibodies against thioredoxin-1
(Cell Signalling Technology, Danvers, USA; 1:1.000) or β-
actin (Santa Cruz, Heidelberg, Germany; 1:1.000), which
served as a loading control. After washing in TBS contain-
ing 0.05% Tween 20 (Sigma-Aldrich), the membranes
were incubated for 1 hour with horseradish peroxidase
conjugated pig anti-rabbit immunoglobulin G (Dako,
Glostrup, Denmark; 1:10.000) referring to the manufac-
turer’s instructions. The final reaction was visualized using
enhanced chemiluminescence (ECL-Detection Reagents,
GE Healthcare, Munich, Germany), and the membrane
was exposed to x-ray film. Images were taken and the in-
tensities of the respective bands were densitometricallyanalysed with the software ImageJ (v1.41o, NIH). Protein
expression levels of thioredoxin were relativized to the
intensity of the respective actin band and depicted as arbi-
trary units (a.u.).
Enzyme Linked Immunosorbent Assay (ELISA)
Human thioredoxin ELISAs (Biozol, Eching, Germany;
#USC-SEA702HU) were performed using unpooled sam-
ples from each patient separately. Briefly, protein extrac-
tion from cardiac tissue biopsies was performed with
RIPA buffer as described above. 50 μg of total protein
from each patient were transferred into each well of a
96-well plate and all further steps were performed ac-
cording to the manufacturer’s protocol. The amount of
thioredoxin was relativized to the total protein within
the respective sample. As suggested in the manufac-
turer’s protocol, hemolytic tissue lysates (HTLs) were ex-
cluded from further analyses (control before CPB, 9
HTLs; control after CPB, 3 HTLs; RIPC before CPB, 0
HTLs; control after CPB, 0 HTLs).
Statistical analysis
Statistics were performed using the software GraphPad
Prism version 5.01 for Windows. Each data set was
tested for normality using the D’Agostino and Pearson
omnibus test. Two way ANOVA in combination with
Bonferroni post-tests were employed for analyses of the
Westernblotting results, while due to missing data points
(excluded HTLs) in the control group, ELISA data were
evaluated using unpaired T-tests. Variables are expressed
as mean ± SEM.
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Profiling of cell stress protein expression in cardiac tissue
Proteome profiling employing cardiac tissue of cardiosur-
gical control patients and cardiosurgical patients undergo-
ing RIPC revealed an increased expression of 26.9% (7/26)
of stress associated proteins in RIPC tissue obtained be-
fore CPB [proteins up-regulated in the RIPC group: Car-
bonic anhydrase IX (CA IX), cytochrome C (Cyt C),
heat shock protein-60 (HSP-60), heat shock protein-70
(HSP-70), phospho JNK (pJNK), superoxide dismutase
2 (SOD2), thioredoxin-1 (Thio-1)], while expression levels
of 3.8% (1/26) of the proteins were down-regulated com-
pared to the control group [proteins down-regulated in
the RIPC group: Sirtuin 2 (SIRT2)]. In cardiac tissue ob-
tained after CPB, only one of the proteins 3.8% (1/26) was
slightly up-regulated in the RIPC group [proteins up-
regulated in the RIPC group: Phospho-p38 alpha (pp38α)]
while compared to the control group, expression levels
of 26.9% (7/26) of the proteins were down-regulated
[proteins down-regulated: Cytochrome C (Cyt C), heat
shock protein-60 (HSP-60), heat shock protein-70 (HSP-
70), phospho heat shock protein-27 (pHSP-27), phospho
JNK (pJNK), sirtuin 2 (SIRT2), thioredoxin-1 (Thio-1);
Figure 2]. A detailed analysis of the protein expression in
control and RIPC cardiac tissue samples obtained before
and after CPB is shown in Figure 3.
Semi-quantitative evaluation of thioredoxin protein
expression in cardiac tissue
One of the proteins that showed a strong expression
within the cardiac tissue and that was also regulated by
RIPC is thioredoxin, a small redox protein and at least
in animal studies, a possible candidate for cardioprotec-
tion [32,33,37,38]. Based on our results of the human
proteome profiling approach which was performed with
pooled tissue samples of the respective patients, we de-
cided to further focus on thioredoxin as a potential mol-
ecule conferring RIPC-mediated cardioprotection and
investigated the expression of thioredoxin in each patient
separately. Westernblotting results mainly confirmed the
outcome of the protein arrays, showing an increased ex-
pression of thioredoxin in cardiac tissue of RIPC patientsFigure 2 Overall regulation of cell stress protein expression in
the RIPC group (compared to the control group) before and
after cardiopulmonary bypass (CPB).that was obtained before CPB (RIPC: 5.36 ± 0.85 a.u.;
control: 3.23 ± 0.39 a.u.; P < 0.05, Figure 4), while no
statistically significant differences in thioredoxin pro-
tein expression levels were detected in samples taken
after CPB (RIPC, 3.94 ± 0.73 a.u.; control, 2.79 ± 0.31 a.u.;
P > 0.05; Figure 4).
Quantification of thioredoxin protein expression in
cardiac tissue
Based on the results of the semi-quantitative Western-
blotting experiments, we furthermore performed thiore-
doxin specific ELISAs to quantify the amount of the
protein within the respective cardiac tissue samples of
each patient and correlate it to the total amount of protein
within the sample. A statistically significant increase of
thioredoxin protein expression was again only detected
in samples of RIPC patients that were obtained before
CPB (RIPC: 0.30 ± 0.02 ng/mg protein; control: 0.24 ±
0.02 ng/mg protein; P < 0.05; Figure 5), while a tendency
towards increased thioredoxin expression was found in
the RIPC tissue samples taken after CPB (RIPC: 0.32 ±
0.03 ng/mg protein; control: 0.25 ± 0.02 ng/mg protein;
P = 0.05; Figure 5).
Discussion
Several clinical trials have suggested RIPC as an efficient
and straightforward intervention to protect the heart from
ischemia reperfusion injury which is a common periopera-
tive complication during various surgical procedures
[8,9,13,16,39-41]. Despite these encouraging clinical data
on RIPC-mediated cardioprotection, the underlying me-
chanisms -especially within the myocardial tissue- are
still discussed controversially [17,20]. Detailed knowledge
about the molecular and cellular events that are associated
with RIPC-mediated cardioprotection could however help
to increase the effectiveness of RIPC and further improve
patient outcome. Therefore, in the last years we have con-
ducted several studies and investigated the effects of RIPC
on ischemia/reperfusion injury in the heart focussing on
the potential mechanisms that transfer the RIPC signal
within the myocardium [26,27,42,43].
In the study presented, we performed proteomic pro-
filing using cardiac tissue from cardiosurgical patients
with cardiopulmonary bypass (CPB) that were subjected
to RIPC or sham intervention.
Several stress associated proteins were found to be
strongly expressed in tissue obtained after CPB. In myo-
cardial samples of the control group, heat shock proteins
(HSP) and especially the phosphorylated form of HSP-27
are up-regulated after CPB. These findings are not sur-
prising as surgery as well as the implementation of the
CPB are stress factors and other groups have also shown
that cardiac surgery results in an increased expression of
heat shock proteins within the respective tissue [44,45].
Figure 3 (See legend on next page.)
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Figure 3 Proteome profiling of cell stress proteins. Equal amounts of protein from control (N = 18) and RIPC patients (N = 18) were pooled
and employed in the array. Only proteins with signal intensities ≥10% of the internal reference control protein spot (not shown) were quantified.
Numbers in the table represent the densitometric intensities of duplicate sample spots. pp38α, phospho-p38 alpha (T181/Y185); HIF2α, hypoxia
inducible factor 2 alpha; ADAMTS1, a disintegrin and metalloproteinase with thrombospondin motifs 1; pp53, phospho-p53 (S46); pHSP-27,
phospho heat shock protein-27; Bcl-2, B cell lymphoma-2; PON1, paraoxonase 1; HSP-60, heat shock protein-60; CA IX, carbonic anhydrase IX;
PON2, paraoxonase 2; HSP-70, heat shock protein-70; Cited2, Cbp/p300-interacting transactivator; PON3, paraoxonase 3; IDO, indoleamine
2,3-dioxygenase; COX-2, cyclooxygenase-2; Thio-1, thioredoxin-1; pJNK, phospho c-Jun n-terminal kinase (T183/Y185); CytC, cytochrome C; SIRT2,
sirtuin 2; NFkB1, nuclear factor kappa B1; Dkk-4, dickkopf-4; SOD2, superoxide dismutase 2; p21/CIP1, cyclin-dependent kinase inhibitor 1A; FABP-1,
fatty acid binding protein-1; - Ctr, negative control; p27, cyclin-dependent kinase inhibitor 1B; HIF1α, hypoxia inducible factor 1 alpha; a.u.,
arbitrary units.
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obtained before CPB, several of the cell stress associated
protein [e.g. HSP-70, cytochrome C (CytC), superoxide
dismutase 2 (SOD2), thioredoxin-1 (Thio-1)] are up-
regulated in the RIPC group. This finding is of major
interest as an increased expression of cell stress proteins
may have a positive effect on the heart [46] and can induceFigure 4 Semi-quantitative evaluation of thioredoxin protein express
cardiac tissue samples of 3 control and 3 RIPC patients. B: Evaluation of the
patients. Numbers in the columns display the numbers of patients employ
kiloDalton; a.u., arbitrary units; columns display the mean; bars denote SEMcardioprotective mechanisms [47-49]. Animal studies
suggested that besides the heat shock proteins, redox
proteins like thioredoxin may also play a role in cardio-
protection [32,33,50,51]. Thioredoxin is a small oxido-
reductase enzyme which is ubiquitously found in many
organisms from plants and bacteria to mammals. It rep-
resents a potent redox protein acting as antioxidant byion. A: Representative Westernblotting experiment performed with
relative protein expression levels of thioredoxin in control and RIPC
ed in the respective experiment. MW, molecular weight; kDa,
; *, P < 0.05, two way ANOVA with Bonferroni post-test.
Figure 5 Quantification of thioredoxin protein expression by
ELISA. The amount of thioredoxin protein is increased in tissue
from RIPC patients that was obtained before CPB. Numbers in the
columns display the numbers of patients employed in the respective
experiment. Columns display the mean; bars denote SEM; *, P < 0.05,
unpaired T-test.
Zitta et al. Journal of Translational Medicine  (2015) 13:34 Page 7 of 9facilitating the reduction of other proteins by cysteine
thiol-disulfide exchange thereby abolishing oxidative
stress within cells and tissues [28,29]. Concerning the
protein expression of thioredoxin within the cardiac tissue,
our cell stress proteome profiler arrays, Westernblotting
experiments and thioredoxin ELISAs all revealed that
RIPC leads to a statistically significant increased expres-
sion of the protein in cardiac tissue obtained before, but
not after CPB. These findings are in accordance with our
recently published studies, which also suggested that
RIPC-mediated effects are mainly evident in tissue derived
before but not in tissue obtained after CPB [26,27]. The
reasons for this observation might be based on the fact
that the immunological response to the extracorporeal
circulation during CPB generates a systemic inflamma-
tory response syndrome (SIRS) that is associated with
the release of various cytokines [52,53] which may
mask possible RIPC-mediated effects in tissue obtained
after CPB. On the other hand, it is known that ische-
mic preconditioning represents a biphasic phenomenon
with a first and a second window of protection [54].
The early phase of protection develops quickly within
minutes from the initial ischemic conditioning event
and lasts for 2 to 3 hours. This is followed by a delayed
phase that begins after 12 to 24 hours and lasts up to
4 days. In our study, samples taken before CPB fall into
the first window of protection, while tissue that is de-
rived after CPB possibly falls into the gap between the
two windows, which explains why only few proteins are
found to be up-regulated by RIPC in tissue samples de-
rived after CPB.
Our findings that several cell stress associated proteins,
including thioredoxin, exhibit a temporary upregulationby RIPC may be of value for future studies employing
RIPC to reduce morbidity and mortality in cardiosurgical
patients. In a clinical perspective, cardiosurgical patients
seem to profit from an early and temporary induction
of cell stress associated proteins by transient episodes
of remote ischemia before surgery. However, the RIPC-
induced response in the remote target organ (e.g. heart)
most likely relies on a delicate balance between protec-
tive and potentially harmful RIPC mediators - circulating
factors as well as local target tissue derived molecules.
The expression of these mediators needs to be precisely
adjusted to exploit the cardioprotective potential of RIPC
and to avoid possible adverse effects of RIPC. Therefore,
optimizing the currently available RIPC protocols [8,55]
by adjusting the RIPC location, timing, duration and cycle
numbers as well as taking into consideration possible
comorbidities of RIPC patients [56] may enhance the
potential of RIPC-mediated cardioprotection, resulting
in an improved patient outcome and may help to re-
duce morbidity as well as mortality after cardiosurgical
interventions.
There are some limitations of the study which need to
be considered: (i) Post-operative or clinical endpoints
were not evaluated in the experimental study presented.
However, clinical outcome parameters are described in
the context of our previous pilot study (Additional file 1:
Table S1; [42,43]). (ii) Depending on the patient and sur-
gical procedure the first biopsy (before CPB) was col-
lected between 15 minutes and 100 minutes after RIPC.
As the second biopsy sample was collected immediately
after CPB the time period between the collection of the
first and second sample varied between the patients. (iii)
Based on surgical and ethical limitations only cardiac tis-
sue of the right atrium and no ventricular tissue could
be obtained and we cannot exclude the possibility that
tissue taken after CPB was affected by e.g. shear stress
induced by the suture of the venous cannula (iv) Due to
methodological constraints and the limited amount of
cardiac tissue available, not all experiments could be per-
formed with samples of all patients. However, it was
assured that in all experiments patients in the RIPC
group had reduced myocardial damage, which was de-
monstrated by significantly lower serum cTnT levels in
the RIPC group.
Conclusions
In the present study we performed proteomic profiling
with heart tissue obtained from cardiosurgical patients
that were subjected to RIPC or sham intervention. We
provide evidence for thioredoxin as a RIPC-induced
factor in the heart of cardiosurgical patients and iden-
tified several cell stress associated proteins that are re-
gulated by RIPC and may play a role in RIPC-mediated
cardioprotection.
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